Citigroup (NYSE:C), Barclays (NYSE:BCS) Underwriting Supernus Pharmaceuticals IPO

Supernus Pharmaceuticals Inc. has filed for an IPO Thursday of $100 million, which will be underwritten by Citigroup Global Markets Inc. (NYSE:C) and Barclays Capital (NYSE:BCS).

The company works on treatments for central nervous systems disorders such as attention deficit disorder and epilepsy.

According to a filing with the SEC, Supernus is seeking approval from the Food and Drug Administration to market SPN-538, a drug used to treat epilepsy.

Capital raised from the IPO will be used for general corporate purposes and the funding of clinical trials.

The company will trade on the Nasdaq under the ticker symbol “SUPN.” The price and number of shares the company will trade haven't been determined yet.

Also participating in underwriting the IPO are Cowen and Co. LLC and Stifel, Nicolaus & Co. Inc.